Announcements

November 18, 2019

OBI Pharma Inc. to attend Investor Conference hosted by Masterlink Securities

[…]
September 16, 2019

Announcement of phase II clinical trial result for ovarian cancer on OBI and Mackay Memorial Hospital cooperated Adagloxad Simolenin, OBI-822

[…]
September 6, 2019

Announcement on change of research and development officer

[…]
August 31, 2019

OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase I/II Study of its Antibody-Drug Conjugate (ADC) targeted cancer therapy, OBI-999

[…]
August 12, 2019

Board of Directors Approved the Change of Financial Officer and Acting Spokesperson

[…]
August 3, 2019

IND Phase I/II Human Clinical Trial Application of Globo-H Antibody-Drug Conjugate, OBI-999, submission to FDA

[…]
July 31, 2019

Announcement on Change of Financial Officer and Acting Spokesperson

[…]
July 29, 2019

Subsidiary AP Biosciences and Tasly Biopharmaceuticals Signed Cooperative Development and Authorized Agreement of New Antibody Drug

[…]
July 22, 2019

Announcement on the Change of Spokesperson

[…]
July 22, 2019

Announcement of New CEO

[…]
July 22, 2019

Announcement of 3rd Audit Committee Members

[…]
July 22, 2019

Announcement of 4th Payroll Committee Members

[…]
July 11, 2019

Taiwan Shilin District Court appeals against the acquittal of Mr. Michael Chang and five other executives’insider trading case

[…]
June 27, 2019

Supplementary statement regarding the news article by the Investor and other news media

[…]
June 27, 2019

Announcement of the status of implementation of the commitments during the up-listing at over-the-counter market

[…]
June 27, 2019

Company’s Board of Directors nominated Michael Chang to serve as the Chairman of the Board

[…]
June 27, 2019

Announcement to Permit Competitive Conduct by Officers

[…]
June 27, 2019

Announcement on Re-election of Board of Directors at the 2019 Annual General Meeting

[…]
June 27, 2019

Announcement of Resolution Items from 2019 Annual General Meeting

[…]
June 24, 2019

Clarification on the news article by internet media on Jun 21,2019

[…]
June 21, 2019

Company Chairman Mr. Michael Chang and other five executives received an acquittal for insider trading case by Taiwan Shilin District Court

[…]
June 17, 2019

Clarification on new article by Economy Daily News dated Jun 16, 2019

[…]
June 15, 2019

OBI-888 completes Phase I safety evaluation and demonstrates its safety and tolerability with no major concerns

[…]
June 14, 2019

Announcement of the company’s cash capital increase and base date

[…]
June 10, 2019

Board of directors of the company waived subscription rights exceeding half of the total subscribable shares. Shares to be subscribed by designated persons

[…]
May 6, 2019

Letter received from National Medical Products Administration (NMPA) of China regarding Adagloxad Simolenin (OBI-822) Phase III clinical study to be resubmitted after supplementation

[…]
April 22, 2019

Supplementary announcement for the company to issue ordinary shares through rights offering

[…]
April 19, 2019

Supplementary announcement for 2019 Annual General Meeting

[…]
April 18, 2019

Announcement for the company to issue ordinary shares through rights offering and bank designated for collection and deposition

[…]
April 13, 2019

Clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study by Ministry of Health of the Russian Federation

[…]
April 9, 2019

Announcement for the company to issue ordinary shares through rights offering

[…]
March 27, 2019

Announcement of capital change registration for the treasury share retirement

[…]
March 8, 2019

The board of directors have resolved not to distribute dividends for 2018

[…]
March 8, 2019

The Board of Directors resolved to hold 2019 Annual General Meeting

[…]
March 8, 2019

Change of accountant due to internal adjustment of the accounting firm

[…]
March 8, 2019

Board of Directors approved the Company’s 2018 individual and consolidated financial statements

[…]
March 8, 2019

Announcement of the resolution of the treasury shares and the establishment of the base date for capital reduction by board of directors

[…]
February 20, 2019

Clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study by Ministry of Health of Ukraine

[…]
February 13, 2019

Clarification on the collaborative publication by OBI Pharma Inc. and Academia Sinica

[…]
January 3, 2019

OBI Pharma Inc. to attend The 37th Annual J.P. Morgan Healthcare Conference

[…]
December 28, 2018

Company Chairman Mr. Michael N. Chang not guilty for the prosecution by Taiwan Shilin District Court

[…]
December 19, 2018

OBI Pharma Inc. to attend 2019 investor conference hosted by Yuanta

[…]
December 3, 2018

OBI Pharma Inc. to attend the Citi’s 2018 Global Healthcare Conference

[…]
November 30, 2018

Announcement of the resolution of the board of directors of the company to issue common shares through rights offering

[…]
November 23, 2018

OBI Pharma Inc. to attend the 2018 Asia Pacific Healthcare Forum, hosted by Goldman Sachs

[…]
November 23, 2018

Clarification on the news article by Up Media and other media groups

[…]
November 21, 2018

OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer

[…]
November 15, 2018

Department of Health (DOH) clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study in Hong Kong

[…]
November 12, 2018

Investigational Device Exemption (IDE) for the development of OBI-888 was approved by the US Food and Drug Administration (FDA) for its use in OBI-888 Phase I cohort expansion phase

[…]
November 2, 2018

Clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study in the United States

[…]
October 29, 2018

OBI Pharma Australia Pty Ltd announces the clearance of Adogloxad Simolenin (OBI-822) for a Phase III clinical study in Australia

[…]
October 1, 2018

OBI received notice from patent attorney’s office that product patent for OBI-822 named “Compound and Compositions of Carbohydrate Vaccine and Uses Thereof” has been approved by Taiwan Intellectual Property Office

[…]
September 28, 2018

Taiwan FDA clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study

[…]
September 20, 2018

Correction on previous announcement: “Clarification on the news article by Commercial Times” to “United Daily News”

[…]
September 20, 2018

Clarification on the news article by Commercial Times

[…]
September 19, 2018

OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)

[…]
September 3, 2018

OBI Pharma Inc. to attend 2018 industry forum hosted by Masterlink Securities

[…]
August 15, 2018

OBI received notice from patent attorney’s office that product patent for OBI-3424 named “DNA alkylating agents” has been approved by IP Australia

[…]
July 30, 2018

Clarification on the news article by Commercial Times

[…]
July 27, 2018

Investigational Device Exemption (IDE) for the development of Adagloxad Simolenin (OBI-822) was approved by the US Food and Drug Administration (FDA) for its use in OBI-822 Phase III Clinical Trial

[…]
July 8, 2018

OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Hepatocellular Carcinoma (HCC)

[…]
June 27, 2018

Announcement on the board resolution at Annual General Meeting 2018

[…]
May 16, 2018

Amendment on the announcement for 2018 Annual General Meeting (discussion notes)

[…]
May 11, 2018

The board of directors of the company resolved to request the shareholders to authorize the board of directors to handle cash-increase of common shares to issue overseas depository receipts

[…]
May 11, 2018

The board of directors of the company resolved to request the shareholders to authorize the board of directors to handle private placement of common shares at the Annual General Meeting

[…]
May 11, 2018

Amendment on the announcement for 2018 Annual General Meeting

[…]
May 11, 2018

Announcement of change of accountant due to internal adjustment of the accounting firm

[…]
April 20, 2018

Announcement based on the procedures for acquisition or disposal of assets

[…]
April 19, 2018

FDA Clearance of OBI-3424 IND Application for A Phase I/II Study Targeting AKR1C3 Solid Tumors

[…]
March 19, 2018

OBI Pharma Inc. to attend Credit Suisse Asian Investment Conference

[…]
March 9, 2018

Announcement on the Change of Chief Financial Officer

[…]
March 9, 2018

OBI Pharma’s Board of Directors approves the announcement of the Company’s 2017 individual and consolidated financial statements

[…]
March 9, 2018

The board of directors have resolved 2017 not to distribute dividends

[…]
March 9, 2018

The Board of Directors resolved to hold 2018 Annual General Meeting

[…]
February 23, 2018

Clarification on the news articles by Commercial Times, United Daily, etc.

[…]
January 17, 2018

FDA Clearance of IND Application for A Phase 1 Study of A Monoclonal Antibody Cancer Immunotherapy (OBI-888)

[…]
January 8, 2018

Shilin District Court deny OBI’s request to submit the case for trial

[…]
January 5, 2018

OBI Pharma Inc. to attend the investor conference on new drug development, hosted by Masterlink Securities

[…]
December 29, 2017

Capital increase for new shares to transfer to AP Biosciences, Inc.

[…]
December 22, 2017

OBI Pharma Inc. to attend the 36th J.P. Morgan Annual Healthcare Conference

[…]
December 5, 2017

OBI Pharma Inc. to attend Citi’s 2017 Global Healthcare Conference

[…]
November 28, 2017

OBI Pharma Inc. to attend the 2017 Asia Pacific Healthcare Forum, hosted by Goldman Sachs

[…]
November 16, 2017

SFIPC and OBI jointly agreed to withdraw the proceedings on Civil case regarding the dismissal of the Chairman of the company.

[…]
October 20, 2017

OBI Plans to Issue New Shares in Exchange for the AP Biosciences, Inc. Shares Owned by AbProtix,Inc, Subject to Regulatory Approval

[…]
October 20, 2017

Announcement on Change of the Accounting Officer

[…]
October 6, 2017

USPTO Approved the Patent Application for OBI-888 “Antibodies, pharmaceutical compositions and uses thereof”

[…]
September 25, 2017

Contract Signing with Pharmacore for the Contract Manufacturing of OBI-858

[…]
August 11, 2017

Announcement on Change of the Acting Spokesperson

[…]
August 11, 2017

Announcement on Change of the Head of Finance and Accounting

[…]
July 21, 2017

OBI Received a Civil Complaint from Taiwan Shilin District Court

[…]
July 12, 2017

Clarification on the news article by China Times

[…]
June 29, 2017

Clarification on the news article by Commercial Times

[…]
June 28, 2017

Important Resolutions of AGM 2017

[…]
June 11, 2017

Supplemental information on the approved application of Phase III clinical trial of OBI-822, the novel breast cancer drug, in China, US, and the EU

[…]
June 1, 2017

OBI Pharma Announces Acquisition of the Novel First-in-class Anti-Cancer Drug OBI-3424 from Threshold Pharmaceuticals to be Developed as Potential Anti-Cancer Therapy for Cancers with High AKR1C3

[…]
April 26, 2017

Announcement of explanation on the first instance judgment of the civil action between the Company against “Next Magazine”

[…]
April 17, 2017

Announcement of explanation on the Company’s criminal lawsuit against Next Magazine

[…]
April 6, 2017

OBI-833, the cancer therapeutic vaccine, has met the primary safety indicators in Phase I clinical trial for US and Taiwan

[…]
March 9, 2017

The board of directors have resolved not to distribute dividends

[…]
March 9, 2017

Announcement by the Company’s Board of Directors to convene the 2016 Annual General Shareholders’ meeting

[…]
March 9, 2017

OBI Pharma’s Board of Directors approves the announcement of the Company’s 2016 individual and consolidated financial statements

[…]
January 26, 2017

Supplemental Information: OBI-822 was approved to enter a Phase III clinical trial by the China Food and Drug Administration (CFDA)

[…]
January 25, 2017

OBI-822 was approved to enter a Phase III clinical trial by the China Food and Drug Administration (CFDA)

[…]
January 23, 2017

OBI Pharma Inc. announces the change of Chief Operating Officer

[…]
January 21, 2017

Clarification on the news article by Commercial Times

[…]
January 11, 2017

Clarification on the news article by United Daily News E-Paper

[…]
January 10, 2017

Clarification on the news article by Economic Daily News

[…]
January 9, 2017

Press release by the Shihlin District Prosecutors Office, Taiwan

[…]
December 30, 2016

Announcement of the signing of a Non-Binding Letter of Intent for OBI Pharma, Inc., to issue new shares to AbProtix, Inc., in exchange for up to 70% stake in AP Biosciences

[…]
December 22, 2016

Clarification on the news article by Economic Daily News

[…]
November 23, 2016

OBI Pharma granted patent approval for its 2nd Generation Active Immunotherapy Treatment by Taiwan and Australia

[…]
November 4, 2016

Clarification on the news article by Economic Daily News E-Paper

[…]
September 23, 2016

To clarify the media report

[…]
September 8, 2016

Additional charges on Next Digital Ltd., Hong Kong

[…]
September 7, 2016

The company was invited to participate in 17th Annual Asian Technology Conference organized by Credit Suisse

[…]
August 31, 2016

To clarify the media report

[…]
August 10, 2016

OBI Pharma Inc. announces the change of VP, Chief Medical Officer

[…]
July 1, 2016

To clarify the media report

[…]
June 27, 2016

Important resolutions of 2016 Annual General Shareholders’ Meeting

[…]
June 27, 2016

The Re-election of Directors at 2016 Annual General Shareholders’ Meeting

[…]
June 27, 2016

OBI Pharma ‘s 2016 Annual General Meeting has approved to release the newly elected Director from non-competition restriction

[…]
June 27, 2016

OBI Pharma, Inc. announces the re-appointment of Mr. Michael Chang as the Chairman of the Company.

[…]
June 15, 2016

The company was invited to participate in the overseas NDR (Non-Deal Roadshow) organized by Credit Suisse, and reported the study results presented in the 2016 ASCO.

[…]
June 14, 2016

OBI Pharma, Inc. will attend Cathay Securities’ Conference on June 16th

[…]
June 7, 2016

To correct the company’s Investor Conference presentation content on June 5 2016

[…]
June 6, 2016

To clarify the media report

[…]
June 5, 2016

The company will publish the clinical study data of the innovation research of OBI-822/OBI-821 for metastatic breast cancer patients at the annual meeting of 2016 ASCO.

[…]
May 30, 2016

Announcement of the Company holding investor presentation and Significant post press conference

[…]
May 30, 2016

Company will hold the Investor Conference

[…]
May 29, 2016

The company states the media’s reports on the related matters of American Society of Clinical Oncology (ASCO).

[…]
May 26, 2016

Media reports that Michael Chang, the chairman of the company, Amy Huang, the general manager and the staffs, six people in total, were guaranteed pending summons for alleged insider trading.

[…]
May 19, 2016

Publication of the Breast Cancer Study Abstract to be presented at ASCO 2016

[…]
May 13, 2016

Board Intentions to apply for long-term fund-raising plan

[…]
May 13, 2016

Supplementary notice on a company board resolution for the upcoming 2016 Annual Shareholders’ Meeting

[…]
May 3, 2016

Company reports outsider suspected of “rumor mongering” intended to manipulate company’s stock, and plans to take legal action against “NEXT Magazine”

[…]
April 22, 2016

OBI Pharma announces the end of the implementation for its first treasury share buyback program

[…]